Charles River Laboratories International Inc (CRL)

Jim Cramer has the game plan for next week, including earnings from Thor Industries and HD Supply.

Charles River Laboratories International, Inc. (NYSE: CRL) recently announced updates to its expanding oncology discovery business, including significant additions to its online Tumor Model Compendium.

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 605,992 share decrease in total short interest for Charles River Laboratories International Inc. , to 1,645,180, a decrease of 26.92% since 04/13/2017.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2017.

Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2017 financial results on Wednesday, May 10 th before the market opens.

The midcap drug maker is finding growth as an outsourcing destination.

Nimbus Therapeutics and Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), announced the North American launch of its triple-immunodeficient mouse model, known as the NCG...

Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), today announced that it has extended its longstanding, strategic, integrated drug discovery partnership...

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Raymond James 38 th Annual Institutional Investors Conference in Orlando, Florida on Tuesday, March 7 th, at 1:05 p.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2016 and provided guidance for 2017.

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 849,583 share increase in total short interest for Charles River Laboratories International Inc. , to 2,167,328, an increase of 64.47% since 01/13/2017.

Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it changed the time of its conference call to discuss fourth-quarter and full-year 2016 financial results and 2017 guidance to 8:00 a.

Charles River Laboratories International, Inc. (NYSE:CRL), a leading early-stage contract research organization (CRO), today announced a progress update related to its support of Moderna Therapeutics'...

Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2016 financial results and provide 2017 guidance on Tuesday, February 14 th, before the market opens.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 35 th Annual J.

Here are Friday's top research calls, including upgrades for Eli Lilly, Regeneron and GE, and downgrades for Nordstrom, Coca-Cola, Apache and Duke Energy.

Charles River Laboratories International, Inc. (NYSE: CRL) today launched a full, end-to-end service offering of CRISPR/Cas9 genome engineering technology.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that its team of leading Central Nervous System (CNS) and neurological disease experts is presenting 25 scientific posters and one podium...

But we could see more volatility in the market.

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2016.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has extended its longstanding integrated drug discovery alliance with Genentech, a member of the Roche Group.

Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2016 financial results on Wednesday, November 2 nd before the market opens.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Agilux Laboratories, Inc.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership agreement with The Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI), intended to...

Impinj is a speculative stock but would be good to own if there's a pullback.

This is not the time to sell in a panic, Cramer says.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences, including: Baird 2016 Global Healthcare Conference in New York on...